Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

159.90 

-1.55 -1.0%

as of Feb 25 '21

52 Week Range:

82.45 212.16


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '13 Dec '14 Mar '15 Dec '15 Mar '16 Dec '16 Mar '17 Dec '17 Mar '18 Dec '18 Dec '19
Equity (BVPS) 1.75
2.23
2.78
2.90
2.70
1.68
3.14
0.99
7.81
8.53
growth rate 27.4% 11.7% 4.3% -6.9% -37.8% 86.9% -68.5% 688.9% 9.2%
Earnings BIT 35.81
-50.51
35.34
-133.16
31.85
-180.50
14.02
-213.32
24.84
-6.39
growth rate -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -100.0%
Avg.PE -13.68
68.88
-13.66
391.41
-2.44
126.76
-2.44
growth rate 100.0% -100.0% 100.0% -100.0% 100.0% -100.0%
ROA 13.79
11.94
9.60
-93.89
6.81
-71.66
1.69
-115.61
5.52
0.11
growth rate -13.4% -10.3% -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -98.0%
ROE 18.65
16.78
13.93
-102.82
11.24
-92.42
3.27
-225.95
9.20
0.17
growth rate -10.0% -8.9% -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -98.2%
ROIC 18.63
16.76
13.92
-102.82
11.24
-72.73
3.27
-138.09
9.20
0.17
growth rate -10.0% -8.9% -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -98.2%
Cur. Ratio 4.21
4.37
4.23
17.90
2.27
4.75
1.90
3.40
3.36
3.17
growth rate 3.8% -1.6% 323.2% -87.3% 109.3% -60.0% 79.0% -1.2% -5.7%
Quick Ratio 3.19
3.50
3.60
17.60
1.65
4.61
1.28
3.35
2.98
2.79
growth rate 9.7% 1.4% 388.9% -90.6% 179.4% -72.2% 161.7% -11.0% -6.4%
Leverage 1.37
1.44
1.46
1.06
1.84
1.78
2.02
2.26
1.54
1.56
growth rate 5.1% 0.7% -27.4% 73.6% -3.3% 13.5% 11.9% -31.9% 1.3%
Balance Sheet Dec '13 Dec '14 Mar '15 Dec '15 Mar '16 Dec '16 Mar '17 Dec '17 Mar '18 Dec '18 Dec '19
Acct.Receivable 30.74
0.97
27.70
0.97
39.47
0.66
56.06
1.75
130.58
146.88
growth rate -96.8% 2,755.8% -96.5% 3,968.7% -98.3% 8,420.4% -96.9% 7,357.4% 12.5%
Acct.Payable 7.68
0.40
7.33
0.62
10.74
8.55
8.59
3.95
56.26
70.88
growth rate -94.8% 1,719.6% -91.5% 1,626.1% -20.4% 0.5% -54.0% 1,324.6% 26.0%
Cur.Assets 134.64
1.11
161.41
282.09
177.23
219.69
205.19
158.26
558.16
619.09
growth rate -99.2% 14,467.6% 74.8% -37.2% 24.0% -6.6% -22.9% 252.7% 10.9%
Total Assets 185.37
1.12
229.88
282.50
278.16
222.54
338.11
160.79
719.54
845.64
growth rate -99.4% 20,480.2% 22.9% -1.5% -20.0% 51.9% -52.5% 347.5% 17.5%
Cash 48.37
276.25
59.53
276.25
40.65
212.57
75.11
154.34
349.46
172.25
growth rate 471.2% -78.5% 364.1% -85.3% 422.9% -64.7% 105.5% 126.4% -50.7%
Inventory 18.32
15.76
34.84
45.47
33.76
38.85
growth rate -7.3% 48.7% 14.2% -13.8% 15.1%
Cur.Liabilities 31.97
3.87
38.14
15.76
78.04
46.27
107.95
46.58
166.01
195.57
growth rate -87.9% 886.0% -58.7% 395.3% -40.7% 133.3% -56.9% 256.4% 17.8%
Liabilities 56.26
8.87
72.88
15.76
127.28
97.70
170.67
89.50
252.22
302.14
growth rate -84.2% 721.8% -78.4% 707.8% -23.2% 74.7% -47.6% 181.8% 19.8%
LT Debt 0.03
51.44
0.08
51.44
0.12
51.44
0.04
42.93
growth rate 177,265.5% -99.8% 63,401.2% -99.8% 43,489.8% -99.9% 104,595.1%
Equity 129.11
-7.75
157.00
266.74
150.89
124.84
167.44
71.29
467.32
543.50
growth rate -100.0% 100.0% 69.9% -43.4% -17.3% 34.1% -57.4% 555.6% 16.3%
Common Shares 54.00
55.00
0.00
55.00
0.00
0.00
0.00
0.00
0.00
58.81
59.50
growth rate 1.9% -100.0% 5,499,900.0% -100.0% 0.0% 0.0% 0.0% 0.0% 5,880,960.0% 1.2%
Cash Flow Statement Dec '13 Dec '14 Mar '15 Dec '15 Mar '16 Dec '16 Mar '17 Dec '17 Mar '18 Dec '18 Dec '19
Capital Expenditures 2.51
0.02
6.00
0.09
4.96
0.11
10.42
4.28
11.14
15.94
growth rate -99.1% 27,691.7% -98.4% 5,173.4% -97.9% 9,822.9% -58.9% 160.0% 43.1%
Cash From OA 35.43
-1.64
46.45
-53.35
21.14
-112.11
18.47
-190.35
63.88
65.67
growth rate -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% 2.8%
FCF per Share 0.48
0.53
0.70
0.60
-0.95
-0.45
-1.92
0.84
0.57
growth rate 10.4% 14.9% -7.4% -100.0% 0.0% 0.0% 100.0% -32.1%
Sale Purchase of Stock 11.00
12.00
2.67
337.64
0.48
0.04
1.38
136.40
235.75
0.11
growth rate 9.1% -77.7% 12,531.7% -99.9% -92.5% 3,741.7% 9,762.3% 72.8% -100.0%
FCF 30.00
33.00
-1.66
40.00
-58.70
9.00
-112.20
7.00
-194.60
52.00
49.00
growth rate 10.0% -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -5.8%
Income Statement Dec '13 Dec '14 Mar '15 Dec '15 Mar '16 Dec '16 Mar '17 Dec '17 Mar '18 Dec '18 Dec '19
Sales 164.53
197.89
268.25
343.80
420.07
530.86
growth rate 9.7% 16.4% 13.2% 10.5% 26.4%
Op.Income 35.81
-50.51
35.34
-133.16
31.85
-180.50
14.02
-213.32
24.84
-6.39
growth rate -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -100.0%
IBT 32.31
-50.51
35.36
-133.16
31.50
-182.01
15.76
-220.65
28.10
2.07
growth rate -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -92.6%
Net Income 19.92
-50.51
19.93
-133.15
17.30
-180.95
5.21
-221.57
29.21
0.88
growth rate -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -97.0%
EPS 0.34
0.37
0.36
-1.41
0.32
-1.82
0.10
-2.06
0.50
0.01
growth rate 8.8% -1.4% -100.0% 100.0% -100.0% 100.0% -100.0% 100.0% -98.0%
Gross Profit 101.55
128.65
170.54
207.09
258.58
307.29
growth rate 12.6% 15.1% 10.2% 11.7% 18.8%
R&D 14.89
34.38
23.61
76.64
30.61
134.78
54.37
141.41
76.86
100.72
growth rate 131.0% -31.3% 224.6% -60.1% 340.3% -59.7% 160.1% -45.7% 31.1%

Quarterly Statements

Item Name Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Earnings BIT 9.33
-11.22
2.08
-10.75
-2.32
growth rate -100.0% 100.0% -100.0% 0.0%
Balance Sheet Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Acct.Receivable 149.01
146.88
147.95
154.25
172.80
growth rate -1.4% 0.7% 4.3% 12.0%
Acct.Payable 50.38
70.88
67.97
104.57
96.56
growth rate 40.7% -4.1% 53.9% -7.7%
Cur.Assets 576.02
619.09
618.74
885.72
875.85
growth rate 7.5% -0.1% 43.2% -1.1%
Total Assets 792.30
845.64
877.45
1,232.91
1,279.15
growth rate 6.7% 3.8% 40.5% 3.8%
Cash 202.55
172.25
156.54
319.25
176.00
growth rate -15.0% -9.1% 103.9% -44.9%
Inventory 40.67
38.85
46.92
81.01
97.61
growth rate -4.5% 20.8% 72.7% 20.5%
Cur.Liabilities 183.83
195.57
195.02
242.83
258.56
growth rate 6.4% -0.3% 24.5% 6.5%
Liabilities 284.66
302.14
317.86
363.10
384.00
growth rate 6.1% 5.2% 14.2% 5.8%
LT Debt 11.54
growth rate
Equity 507.65
543.50
559.59
869.81
895.15
growth rate 7.1% 3.0% 55.4% 2.9%
Common Shares 59.32
59.50
59.81
63.47
63.55
growth rate 0.3% 0.5% 6.1% 0.1%
Cash Flow Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Capital Expenditures 4.25
3.83
2.21
5.34
58.47
growth rate -9.9% -42.3% 141.8% 994.6%
Cash Dividends
growth rate
Cash From OA 22.44
45.81
13.42
-20.39
11.14
growth rate 104.1% -70.7% -100.0% 100.0%
Sale Purchase of Stock 0.00
0.01
0.03
307.05
growth rate 300.0% 250.0% 1,096,492.9%
FCF 18.19
41.98
11.21
-25.73
-47.33
growth rate 130.8% -73.3% -100.0% 0.0%
Income Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Sales 130.84
171.85
147.16
141.26
166.44
growth rate 31.4% -14.4% -4.0% 17.8%
Op.Income 6.62
-14.39
-0.80
-13.68
-5.45
growth rate -100.0% 0.0% 0.0% 0.0%
IBT 8.44
-11.90
0.14
-12.06
-3.41
growth rate -100.0% 100.0% -100.0% 0.0%
Net Income 6.10
-12.38
4.07
-30.76
-0.87
growth rate -100.0% 100.0% -100.0% 0.0%
Gross Profit 80.17
92.64
88.61
88.18
98.24
growth rate 15.6% -4.4% -0.5% 11.4%
R&D 25.13
75.45
26.38
29.56
29.25
growth rate 200.3% -65.0% 12.1% -1.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (44.62)

YOY Growth Grade:

F (15.55)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -2.44 -128.02 -1.21
EPS / Growth 0.0% -1.25

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 25.0% 25.8%
Future PE 0.00 0.01 17.17
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.